The new campus aims to employ approximately 350 employees, ranging from production operators to design engineers and quality specialists.
The US-based company and owner of Phillips-Medisize said that the Polish campus will boast technological advances such as advanced medical device assembly, packaging, drug handling and injection moulding.
Set to open in the city of Katowice, the facility marks the 7th facility for the Molex subsidiary in the European Union, joining production sites in Ireland, the Czech Republic, Denmark and Finland, the last of which produces Phillips-Medisize’s needle-free continuous glucose monitor.
Senior vice president for Phillips-Medisize, Paul Chaffin said: “The Katowice campus will expand our European footprint, providing our pharmaceutical, diagnostic and medtech customers with new capabilities and the expert support they need to bring innovative new products to market.
“This ultimately allows us to further our vision of enabling patients all over the world to live healthier, more productive lives. We look forward to becoming an active part of the local community, as we work together to create significant value for our customers, our new team members and ultimately patients.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Chaffin added: “The Katowice campus will expand our European footprint, providing our pharmaceutical, diagnostic and medtech customers with new capabilities and the expert support they need to bring innovative new products to market.”
GlobalData’s Medical Device Intelligence Centre details how Phillips-Medisize currently has five marketed products across the United States and Europe, ranging from drug delivery devices such as the Aria Smart Autoinjector Platform, to healthcare IT systems.